BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36759880)

  • 1. Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer.
    Kong D; Ye C; Zhang C; Sun X; Wang F; Chen R; Xiao G; He S; Xu J; Rao X; Ai J; Gao X; Li H; Su L
    J Exp Clin Cancer Res; 2023 Feb; 42(1):45. PubMed ID: 36759880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
    Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
    Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.
    Morrissey C; Lai JS; Brown LG; Wang YC; Roudier MP; Coleman IM; Gulati R; Vakar-Lopez F; True LD; Corey E; Nelson PS; Vessella RL
    Prostate; 2010 Mar; 70(4):412-24. PubMed ID: 19866469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canine prostatic cancer cell line (LuMa) with osteoblastic bone metastasis.
    Elshafae SM; Dirksen WP; Alasonyalilar-Demirer A; Breitbach J; Yuan S; Kantake N; Supsavhad W; Hassan BB; Attia Z; Alstadt LB; Rosol TJ
    Prostate; 2020 Jun; 80(9):698-714. PubMed ID: 32348616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Icariin inhibits prostate cancer bone metastasis and destruction via suppressing TAM/CCL5-mediated osteoclastogenesis.
    Chen C; Wang S; Wang N; Zheng Y; Zhou J; Hong M; Chen Z; Wang S; Wang Z; Xiang S
    Phytomedicine; 2023 Nov; 120():155076. PubMed ID: 37716031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ADAM9/WISP-1 axis cooperates with osteoblasts to stimulate primary prostate tumor growth and metastasis.
    Chang AC; Lin LW; Chen YC; Chen PC; Liu SC; Tai HC; Wu HC; Sung SY; Lin TH; Tang CH
    Int J Biol Sci; 2023; 19(3):760-771. PubMed ID: 36778124
    [No Abstract]   [Full Text] [Related]  

  • 9. Notch3 promotes prostate cancer-induced bone lesion development via MMP-3.
    Ganguly SS; Hostetter G; Tang L; Frank SB; Saboda K; Mehra R; Wang L; Li X; Keller ET; Miranti CK
    Oncogene; 2020 Jan; 39(1):204-218. PubMed ID: 31467432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
    Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB
    Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1-targeting miRNA-92a-1-5p.
    Yu L; Sui B; Fan W; Lei L; Zhou L; Yang L; Diao Y; Zhang Y; Li Z; Liu J; Hao X
    J Extracell Vesicles; 2021 Jan; 10(3):e12056. PubMed ID: 33489015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caprylic acid (C8:0) promotes bone metastasis of prostate cancer by dysregulated adipo-osteogenic balance in bone marrow.
    Wang C; Wang J; Chen K; Pang H; Li X; Zhu J; Ma Y; Qiu T; Li W; Xie J; Zhang J
    Cancer Sci; 2020 Oct; 111(10):3600-3612. PubMed ID: 32770813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
    Keller ET; Brown J
    J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases.
    Kirschenbaum A; Izadmehr S; Yao S; O'Connor-Chapman KL; Huang A; Gregoriades EM; Yakar S; Levine AC
    Endocrinology; 2016 Dec; 157(12):4526-4533. PubMed ID: 27783536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic Prostate Cancer Cells Secrete Methylglyoxal-Derived MG-H1 to Reprogram Human Osteoblasts into a Dedifferentiated, Malignant-like Phenotype: A Possible Novel Player in Prostate Cancer Bone Metastases.
    Antognelli C; Marinucci L; Frosini R; Macchioni L; Talesa VN
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
    Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
    Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
    Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
    J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A.
    Hashimoto K; Ochi H; Sunamura S; Kosaka N; Mabuchi Y; Fukuda T; Yao K; Kanda H; Ae K; Okawa A; Akazawa C; Ochiya T; Futakuchi M; Takeda S; Sato S
    Proc Natl Acad Sci U S A; 2018 Feb; 115(9):2204-2209. PubMed ID: 29440427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling.
    Dai Y; Wu Z; Lang C; Zhang X; He S; Yang Q; Guo W; Lai Y; Du H; Peng X; Ren D
    Theranostics; 2019; 9(21):6063-6079. PubMed ID: 31534537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.